Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
-0.29% $17.29
America/New_York / 19 apr 2024 @ 10:19
FUNDAMENTALS | |
---|---|
MarketCap: | 1 463.06 mill |
EPS: | 2.30 |
P/E: | 7.52 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 84.62 mill |
Avg Daily Volume: | 1.576 mill |
RATING 2024-04-18 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Neutral | |
P/E: | Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 7.52 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.03x |
Company: PE 7.52 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$32.63 (88.72%) $15.34 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 16.65 - 18.21 ( +/- 4.46%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2012-09-20 | Sagard Capital Partners, L.p. | Buy | 1 000 | Common Stock |
2012-09-20 | Howe Michael C | Sell | 5 556 | Common Stock |
2012-06-10 | Sagard Capital Partners, L.p. | Sell | 0 | Common Stock |
2012-01-03 | Howe Michael C | Buy | 5 556 | Common Stock |
2011-08-24 | Howe Michael C | Buy | 0 |
INSIDER POWER |
---|
0.00 |
Last 99 transactions |
Buy: 2 558 547 | Sell: 23 556 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $17.29 (-0.29% ) |
Volume | 0.177 mill |
Avg. Vol. | 1.576 mill |
% of Avg. Vol | 11.26 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.35 | N/A | Active |
---|
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.